- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.02. | Thermo Fisher continues viral vector withdrawal; lays off 300 employees | ||
| 04.02. | USC receives grant for gene therapy targeting glioblastoma | ||
| 04.02. | Immunotherapeutic responses and their assessments | ||
| 04.02. | World Cancer Day: WHO warns of rising cancer burden in Southeast Asia | ||
| 04.02. | Vanda and AnaptysBio link for generalised pustular psoriasis therapy | ||
| 04.02. | Microplastics: the silent threat | ||
| 04.02. | AstraZeneca lung cancer therapy Imfinzi recommended for EU approval | ||
| 04.02. | People-focused care demands policy support | ||
| 03.02. | AdvanCell raises $112m as radiopharma buzz continues | ||
| 03.02. | MHRA seeks input on new regulatory guidance for cancer vaccines | ||
| 03.02. | Pfizer's colon cancer combo approval further supported by Phase III win | ||
| 03.02. | Celltrion's Avtozma receives FDA approval for multiple conditions | ||
| 03.02. | Sanofi kicks off share buyback plan with $3bn L'Oréal stake purchase | ||
| 03.02. | Sanofi's Sarclisa combo approved in China for multiple myeloma | ||
| 03.02. | ViiV Healthcare and J&J's adolescent HIV-1 combo gains EC authorisation | ||
| 31.01. | EMA recommends Bavarian Nordic's chikungunya vaccine for adults and teenagers | ||
| 31.01. | Rentschler closes UK cell and gene therapy facility and does a pivot to biologics | ||
| 31.01. | Roche targets continued growth after strong 2024 sales | ||
| 31.01. | All change in Germany - confidential pricing in, IRP out | ||
| 31.01. | Sanofi reports Q4 2024 increase in net income to $916m | ||
| 31.01. | Top 20 biopharma companies' market caps rise 1.7% over 2024 amid policy | ||
| 31.01. | NHS England to offer Casgevy for sickle cell disease patients | ||
| 31.01. | Protected: How AI is streamlining cell and gene therapy manufacturing | ||
| 31.01. | Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO | ||
| 31.01. | FDA approves Vertex's acute pain treatment Journavx |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
